FDA grants Breakthrough Device designation to ReVision Implant's Occular visual cortical prosthesis

The Lazaretto keeps its watch on the water-world’s medicine.

On March 9, 2026, ReVision Implant said the FDA granted Breakthrough Device designation to Occular, a visual cortical prosthesis intended to restore a degree of functional vision to people with severe blindness. Rather than targeting the retina or the optic nerve, the device interfaces directly with the brain’s visual cortex, bypassing damage to the eye or the visual pathway.

A wireless headset camera captures the scene and transmits it to the implant, which stimulates cortical neurons to produce perceived points of light. Those points combine into simple images intended to help a user recognize objects and navigate a space. The approach is aimed at patients whose blindness cannot be addressed by retinal implants or optic-nerve therapies.

The Belgian company said the designation gives it earlier access to FDA feedback on regulatory and clinical trial planning. It anticipates a short-term test during a scheduled brain surgery in October 2026, with early-stage trials in blind volunteers potentially beginning in 2027, pending regulatory clearance.